![]() There are scant data regarding the effect of apixaban on traditional coagulation testsĬurrently, there is no FDA-approved specific antidote for this class of anticoagulants Prevents factor Xa-mediated conversion of prothrombin to thrombin RFVIIa or FFP are not recommended in direct thrombin inhibitor-related ICH (Strong recommendation, low-quality evidence) Irreversible direct inhibition of thrombin (factor IIa) including thrombin-mediated platelet activation and aggregationĪPCC (50 units/kg) or four-factor PCC (50 units/kg) (Conditional recommendation, low-quality evidence) ICH distribution: 46 % intraparenchymal, 45 % SDH, and 8 % SAH Hemodialysis if idarucizumab is not available (Conditional recommendation, low-quality data) Hemodialysis (approximately 57 % over 4 hours)Īntifibrinolytic agent (e.g., tranexamic acid, epsilon-aminocaproic acid) Idarucizumab 5 g IV in two divided doses if dabigatran was administered within 3–5 half-lives and no RF (Strong recommendation, moderate quality of evidence) or in the presence of RF leading to continued drug exposure beyond the normal 3–5 half-lives (Strong recommendation, moderate quality of evidence)Īctivated charcoal if last dose was taken < 2 hours Idarucizumab or Praxbind® (humanized antibody fragment against dabigatran), in two doses of 2.5 g IV 15 minutes apart ![]() Modified TT/ECT/prolongs PT linearly with increasing serum levels, while aPTT is affected in a nonlinear way Withhold VKA + intravenous vitamin K + replace vitamin K–dependent factors (three- or four-factor PCC IV or FFP if PCCs are not available), and correct the INR (keep INR 80 % renal
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |